Ticker Details
Bio-Path Holdings, Inc. Bio-Path Holdings Inc is a clinical and preclinical stage oncology focused antisense drug development company utilizing novel technology achieving systemic delivery for specific protein inhibition for any gene product that is over-expressed in disease.
IPO Date:	April 1, 2008
Sector:	Healthcare
Industry:	Biotech
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 4.21%
Avg Daily Range (30 D):	$0.01 | 11.36%
Avg Daily Range (90 D):	$0.01 | 14.02%

Institutional Daily Volume
Avg Daily Volume:	.2M
Avg Daily Volume (30 D):	.01M
Avg Daily Volume (90 D):	.02M

Trade Size
Avg Trade Size (Sh.):	87
Avg Trade Size (Sh.) (30 D):	1,889
Avg Trade Size (Sh.) (90 D):	1,832

Institutional Trades
Total Institutional Trades:	54
Avg Institutional Trade:	$2.04M
Avg Institutional Trade (30 D):	$.98M
Avg Institutional Trade (90 D):	$.98M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.13M
Avg Closing Trade (30 D):	$M
Avg Closing Trade (90 D):	$M
Avg Closing Volume:	1.46K

News

Jun 3, 2025 @ 11:00 AM Bio-Path Holdings Provides Clinical and Operationa... Source: Bio-Path Holdings, Inc.

Jan 10, 2025 @ 12:00 PM Bio-Path Holdings Provides 2025 Clinical and Opera... Source: Bio-Path Holdings, Inc.

Dec 11, 2024 @ 12:00 PM Bio-Path Holdings Outlines Rationale for Developme... Source: Bio-Path Holdings, Inc.

Oct 9, 2024 @ 12:00 AM Bio-Path Holdings Announces $4.0 Million Private P... Source: Bio-Path Holdings, Inc.

Sep 3, 2024 @ 11:00 AM Bio-Path Holdings to Present at H.C. Wainwright 26... Source: N/A

Financials
	TTM	FY 2024	Q3 2024
Basic EPS	$-.07	$-4.12	$-.7
Diluted EPS	$-.07	$-4.12	$-.7
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-2.75M	$-9.89M	$-2.12M
Operating Income / Loss	$-2.63M	$-11.99M	$-2.63M
Cost of Revenue
Net Cash Flow	$M	$M	$M
PE Ratio

Splits
Feb 23, 2024	1:20
Jan 18, 2019	1:20
Feb 09, 2018	1:10